CA3240515A1 - Gap junction modulators and their use for the treatment of age-related macular degeneration - Google Patents

Gap junction modulators and their use for the treatment of age-related macular degeneration Download PDF

Info

Publication number
CA3240515A1
CA3240515A1 CA3240515A CA3240515A CA3240515A1 CA 3240515 A1 CA3240515 A1 CA 3240515A1 CA 3240515 A CA3240515 A CA 3240515A CA 3240515 A CA3240515 A CA 3240515A CA 3240515 A1 CA3240515 A1 CA 3240515A1
Authority
CA
Canada
Prior art keywords
compound
treatment
prevention according
amd
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3240515A
Other languages
English (en)
French (fr)
Inventor
Ulrik Mouritzen
Bradford YOUNG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Breye Therapeutics ApS
Original Assignee
Breye Therapeutics ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Breye Therapeutics ApS filed Critical Breye Therapeutics ApS
Publication of CA3240515A1 publication Critical patent/CA3240515A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3240515A 2021-12-22 2022-12-21 Gap junction modulators and their use for the treatment of age-related macular degeneration Pending CA3240515A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163292783P 2021-12-22 2021-12-22
US63/292,783 2021-12-22
PCT/EP2022/087342 WO2023118366A1 (en) 2021-12-22 2022-12-21 Gap junction modulators and their use for the treatment of age-related macular degeneration

Publications (1)

Publication Number Publication Date
CA3240515A1 true CA3240515A1 (en) 2023-06-29

Family

ID=84981302

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3240515A Pending CA3240515A1 (en) 2021-12-22 2022-12-21 Gap junction modulators and their use for the treatment of age-related macular degeneration

Country Status (9)

Country Link
US (1) US20250018002A1 (https=)
EP (1) EP4452260B1 (https=)
JP (1) JP2025500123A (https=)
CN (1) CN118450892A (https=)
CA (1) CA3240515A1 (https=)
DK (1) DK4452260T3 (https=)
FI (1) FI4452260T3 (https=)
IL (1) IL313729A (https=)
WO (1) WO2023118366A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202310195D0 (en) * 2023-07-03 2023-08-16 Hastings Nataly Method for mitigating symptoms of neurological condition and a system therefor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6259296A (ja) 1985-09-10 1987-03-14 Green Cross Corp:The ペプタイド誘導体
IL157447A0 (en) 2001-02-22 2004-03-28 Zealand Pharma As Zealand Phar New medical uses of intercellular communication facilitating compounds
UA96283C2 (uk) 2005-12-23 2011-10-25 Зіланд Фарма А/С Модифіковані міметики лізину
PL2468724T3 (pl) 2006-12-21 2016-05-31 Zealand Pharma As Synteza związków pirolidynowych
JP6989864B2 (ja) * 2017-05-05 2022-02-03 ジーランド ファーマ，アー／エス ギャップ結合細胞間コミュニケーションモジュレータ及び糖尿病性眼疾患の治療のためのそれらの使用

Also Published As

Publication number Publication date
WO2023118366A1 (en) 2023-06-29
US20250018002A1 (en) 2025-01-16
EP4452260B1 (en) 2026-01-28
EP4452260A1 (en) 2024-10-30
JP2025500123A (ja) 2025-01-09
IL313729A (en) 2024-08-01
FI4452260T3 (fi) 2026-03-30
CN118450892A (zh) 2024-08-06
DK4452260T3 (da) 2026-03-30

Similar Documents

Publication Publication Date Title
US10799552B2 (en) Methods for treating diabetic neurotherapy
CA2671613C (en) Methods of use of trk receptor modulators
Andrés-Guerrero et al. Targeting Schlemm’s canal in the medical therapy of glaucoma: current and future considerations
US20160367619A1 (en) Methods and compositions for preserving retinal ganglion cells
US20220133866A1 (en) Method for the Treatment of a Disease Using Pigment Epithelium-Derived Factor (PEDF)
EP4452260B1 (en) Gap junction modulators and their use for the treatment of age-related macular degeneration
US11324799B2 (en) Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease
KR20210003061A (ko) Mct 발현 또는 활성 억제제를 유효성분으로 포함하는 혈관신생 관련 안과 질환의 예방 또는 치료용 약학적 조성물
US20230338483A1 (en) Method for the treatment of a disease using pigment epithelium-derived factor (pedf)
EA051681B1 (ru) Модуляторы щелевых контактов и их применение для лечения возрастной макулярной дегенерации
US20220280473A1 (en) Compositions and methods for modulating epithelial-mesenchymal transition
JP7795359B2 (ja) 上皮および関門の完全性を保護するための組成物および方法
US10973867B2 (en) Compositions and methods for treating retinopathy
HK40000030B (en) Compositions and methods for treating retinopathy
HK1143544A (en) The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251124

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251124